[ad_1]
On Monday, Pfizer and Biontech announced promising information about the companies’ joint vaccine candidate. According to preliminary data from phase 3 studies, more than 90 percent had developed protection against the disease 28 days after the first and seven days after the second dose of the vaccine.
– We reached a decisive milestone in the vaccine development program at a time when the world needs it most, says Albert Bourla.
According to the companies, the study so far shows not about the worrisome health risks with the vaccine.
The study has not yet been published in a scientific journal, nor has it been reviewed and approved by other researchers. Clinical trials continue to collect more data.
The companies plan to apply for emergency approval in the US in late November. Upon approval, doses will initially be limited. According to Pfizer and Biontech’s own estimates, 50 million doses will be produced in 2020 and 1.3 billion in 2021.
Read more:
Sweden Coordinator: Here are the most promising vaccines against covid-19
Astra Zeneca CEO: We may be able to start vaccinating in late December
